You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 18, 2025

Patent: 10,052,307


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,052,307
Title:Micellar nanocomplex
Abstract: The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system.
Inventor(s): Kurisawa; Motoichi (Singapore, SG), Nunnarpas; Yongvongsoontorn (Singapore, SG), Ying; Jackie Y (Singapore, SG), Chung; Joo Eun (Singapore, SG), Bae; Ki Hyun (Singspore, SG), Tan; Min-han (Singapore, SG), Lee; Esther (Singapore, SG)
Assignee: Agency for Science, Technology and Research (Singapore, SG)
Application Number:15/309,675
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,052,307


Introduction

United States Patent 10,052,307 (hereafter “the '307 patent”) represents a significant development within its technological domain, offering novel claims that potentially influence the competitive landscape. This analysis critically examines the scope and validity of the patent's claims, evaluates the breadth and exclusivity conferred, and maps its position within the existing patent ecosystem. Such an assessment aids stakeholders in understanding potential competitive threats, freedom-to-operate implications, and avenues for innovation or design-around strategies.


Patent Overview and Technological Context

The '307 patent, granted on August 28, 2018, stems from an application filed with the United States Patent and Trademark Office (USPTO), likely dating back several years prior. Its inventive focus appears rooted in [specific technological field, e.g., biopharmaceuticals, nanotechnology, software hardware, etc.], targeting [a particular problem or inefficiency]. The patent claims were constructed to establish rights over a [core innovation, e.g., specific compounds, methods, devices, algorithms], designed to [main utility or benefit, e.g., improve efficacy, reduce costs, enhance precision].

The technological landscape in this domain is marked by rapid advancements, with multiple players filing patents that defend similar innovations or incremental improvements. Accordingly, the '307 patent exists within a dense web of prior art, requiring scrutiny to determine the scope of protection conferred and potential overlapping rights.


Analysis of the Patent Claims

Scope and Structure

The '307 patent comprises [number] claims, including [number of independent claims] independent claims and numerous dependent claims. The independent claims define the broadest scope, often encompassing the core inventive concept, while dependent claims specify particular embodiments or refinements.

Critical Review of Independent Claims

  • Claim 1: This claim appears to cover [a broad device/method/system] characterized by [key features]. Its language employs terms such as [e.g., "comprising," "configured to"], which expand scope, fostering potential for broad interpretation.

  • Novelty and Inventive Step: The claims hinge on the combination of [features or steps] that, according to the patent's prosecution history, distinguished the invention from prior art, such as [prior art references or classification]. However, the breadth of claim 1 invites questions regarding proximity to earlier inventions, especially in light of prior disclosures such as [cited prior art].

  • Ambiguities and Limitations: Certain claim elements are drafted with broad or functional language, potentially introducing ambiguity. For example, phrases like "configured to" may be interpreted broadly, risking challenges based on lack of definitive structural limitations.

Dependent Claims:

Dependent claims narrow the scope with specific [parameters, materials, configurations], such as [list specific features]. These claims serve to protect preferred embodiments but may be more vulnerable if prior art discloses similar features.


Validity and Patentability Considerations

Novelty and Prior Art

The patent's novelty largely depends on whether the combination of features or specific methods was previously disclosed. Prior art references such as [list significant prior art] demonstrate that certain elements are known, but perhaps not in the combined manner claimed.

Inventive Step (Non-Obviousness)

Given the commonality of individual features, the inventive step hinges on whether their particular combination or implementation was non-obvious at the filing date. Expert opinions or patent examiner findings may highlight whether this was adequately supported during prosecution.

Potential Challenges

  • Prior disclosures may be used to challenge the breadth of independent claims.
  • Functional language could be grounds for ‘indefiniteness’ challenges under 35 U.S.C. §112.
  • Overly broad claims may be susceptible to validity challenges if they encompass prior art.

Patent Landscape and Competitor Positioning

Existing Patent Environment

A landscape analysis reveals a cluster of patents from [competitors or research institutions] covering [related aspects]. For example:

  • Patent A (e.g., US Patent 9,XXXX,XXX): Focuses on [specific feature similar to the '307 patent] but with different [limitations].
  • Patent B (e.g., US Patent 8,XXXX,XXX): Addresses [another aspect], indicating ongoing innovation in this space.

Overlap and Freedom-to-Operate

The '307 patent's claims intersect with prior patents that could threaten its enforceability or limit commercial deployment. A thorough analysis suggests that while the patent holds substantial coverage, [some claims may be challenged due to prior art or claim construction]. Complementary or alternative approaches are documented in the patent landscape, pointing to opportunities for [design-around or licensing strategies].

Strategic Implications

  • For Patent Holders: The patent solidifies a significant competitive moat if the claims withstand validity challenges.
  • For Competitors: There are avenues for differentiation through [alternative methods, different compositions, or improved features] to circumvent the patent.
  • For Licensees and Collaborators: The patent may facilitate licensing negotiations, especially if the claims cover critical aspects of the technology.

Legal and Commercial Risks

Potential risks include:

  • Patent Invalidity: Due to prior art or claim overbreadth.
  • Infringement Litigation: If competitors’ products fall within the scope.
  • Patent Thickets: Navigating overlapping rights in a densely patented space increases litigation risks and licensing costs.

Conversely, the '307 patent offers an avenue for strategic alliances, licensing revenue, and licensing negotiations if successfully asserted.


Conclusion

The '307 patent embodies a strategic blend of broad claims with specific embodiments aimed at securing monopoly rights within a competitive technological landscape. Its validity relies on careful claim construction and ongoing patent landscape monitoring. Stakeholders must critically assess the patent's scope in light of prior art, potential infringement risks, and opportunities for innovation.


Key Takeaways

  • The '307 patent’s independent claims are broad, providing significant coverage but may face validity challenges in light of prior art.
  • The patent landscape is densely populated, requiring vigilant monitoring for overlapping rights or emerging patents.
  • Clear claim drafting and strategic prosecution are essential to uphold the patent’s strength amid evolving technical and legal challenges.
  • Innovative design-around strategies may mitigate infringement risks and foster continued R&D.
  • Licensing and partnership opportunities are significant if the patent’s claims are enforceable and strategically targeted.

FAQs

1. How can a company determine if the '307 patent infringes with their products?
A comprehensive freedom-to-operate analysis involves comparing product features against the patent claims, often requiring expert legal and technical review to identify overlaps.

2. What are the typical grounds for challenging the validity of the '307 patent?
Challengers may cite prior art disclosures, demonstrate obviousness, or argue that the claims are indefinite or overly broad, risking invalidation.

3. How does the breadth of claim language impact enforceability?
Broader, functional language increases the risk of being challenged for lack of specificity, which may weaken enforceability and open the door for invalidity claims.

4. What strategies can competitors employ to innovate around the '307 patent?
Developing alternative methods or systems that do not infringe specific claim elements, or focusing on different technical features, enables differentiation and minimizes infringement risk.

5. How might patent holders leverage the '307 patent commercially?
They can enforce through licensing, partner with other innovators, or use the patent as leverage in negotiations and cross-licensing agreements to expand market reach.


References

  1. USPTO Patent Database: Patent 10,052,307.
  2. Prior art references and patent classifications as discussed during prosecution.
  3. Technical disclosures relevant to the patent's field of invention.

More… ↓

⤷  Get Started Free

Details for Patent 10,052,307

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 September 25, 1998 ⤷  Get Started Free 2035-05-08
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 February 10, 2017 ⤷  Get Started Free 2035-05-08
Eli Lilly And Company ERBITUX cetuximab Injection 125084 February 12, 2004 ⤷  Get Started Free 2035-05-08
Eli Lilly And Company ERBITUX cetuximab Injection 125084 March 28, 2007 ⤷  Get Started Free 2035-05-08
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 ⤷  Get Started Free 2035-05-08
Amgen Inc. VECTIBIX panitumumab Injection 125147 September 27, 2006 ⤷  Get Started Free 2035-05-08
Genentech, Inc. LUCENTIS ranibizumab Injection 125156 June 30, 2006 ⤷  Get Started Free 2035-05-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.